To further validate SRC’s role as a mediator of the response to vemurafenib, we knocked down SRC using short hairpin RNA (shRNA) (Fig. 2d) and found that SRC-deficient BRAFV600E CRC cells were more sensitive to vemurafenib treatment in 3-day viability and colony formation assays (Fig. 2e,f), although, as expected, the effect was not as profound as when using SFK inhibitors. Here, SRC is linked to colorectal carcinoma.